The longevity industry loves to celebrate discovery. We romanticize the eureka moment in the lab, the new mechanism unearthed, the biomarker that might finally bend the curve of human healthspan. Yet, as investors move from curiosity to disciplined capital allocation, a quiet shift is happening: they are no longer funding discovery alone, they are funding ownership.
This was the central undercurrent in a recent conversation with Dr. Herna De Wit, who bridges two worlds most founders rarely see in the same room: she holds a PhD in Biochemistry and an LLB in Law, and now advises longevity and health‑tech companies on how to turn evidence and intellectual property into investable businesses.
What emerged from that discussion is a simple but uncomfortable truth for many founders in longevity, beauty, diagnostics, and wellness: great science is no longer enough.
When Science Becomes a Business Discipline
For years, early longevity entrepreneurs mostly asked one question: “Does it work?” If a molecule improved mitochondrial function, if a protocol moved biological age markers, if a device shifted stress or sleep metrics, that was considered “enough” to justify a launch. Today, especially in rooms where serious capital sits, the question set has expanded.
Investors now want to know:
- Can it be patented, and in which jurisdictions?
- Can competitors copy it easily, or is there a technical and legal moat?
- Who really owns the IP—the founder, the university, a contractor, or a previous employer?
- Is there freedom to operate, or are there landmines of prior patents waiting to be triggered by scale?
In other words, intellectual property has become a proxy for credibility. It is not because a single patent guarantees success, but because a thoughtful IP strategy suggests the founders understand how to move from experiment to enduring enterprise.
This is particularly relevant in the areas now reshaping beauty and longevity: NAD+ and cellular energy, senescence modulation, mitochondrial health, biological age testing, skin longevity, AI‑powered personalization, diagnostics, and wearables.
Many teams in these verticals speak fluently about mechanisms and biomarkers, but far fewer can explain how their science is protected, commercialized, and defended.
Read more: Diagnostics & Biological Age
The Ingredient Myth: Why “Natural” Does Not Mean “Unprotectable”
One of the most persistent myths in beauty and longevity is that natural or well‑known ingredients cannot be protected at all. Founders working with spermidine, NAD+ precursors, peptides, exosomes, adaptogens, probiotics, and other mitochondrial and microbiome‑active compounds regularly say: “We can’t patent this; it’s already in the literature.”
What Dr. De Wit and other IP strategists point out is that this framing is too narrow. While it is often difficult to patent a molecule that is clearly prior art, there is usually far more room around that molecule than founders realize. Depending on the jurisdiction and the evidence, companies may be able to protect:
- Novel delivery systems that change how and where the ingredient acts
- Specific formulations and ratios that create emergent effects
- Manufacturing methods that improve stability or bioavailability
- Diagnostic or personalization frameworks that link the ingredient to precise protocols
- Integrated systems that combine hardware, software, and biology in unique ways
The competitive advantage for longevity beauty is increasingly not the ingredient itself, but the system around it: how it is delivered, combined, tracked, and translated into outcomes. Ignoring this dimension leaves brands vulnerable in precisely the moment when their science begins to succeed.
Strong Science, Weak Claims: The Cost of Poor Patents
If the ingredient myth is the first trap, the second is more painful: assuming that strong science automatically leads to strong protection. The industry has already seen high‑profile disputes—such as litigation around nicotinamide riboside (NR)—where compelling biology was undermined by fragile or poorly framed patent claims.
The pattern is instructive. A company invests heavily in developing a compound, demonstrating mechanisms, and building early market traction.
Yet, when challenged in court or examined in depth, the patents fail to hold, are narrowed significantly, or invalidated altogether. The outcome is not just legal embarrassment; it is the loss of exclusivity after years of scientific and commercial effort.
For longevity founders, the takeaway is clear: patent drafting is not an administrative box‑ticking exercise. It is a strategic act that must be aligned with the biology, the business model, and the long‑term category vision.
A weak patent can destroy value just as surely as failed clinical data—only more quietly and often later, when the stakes are highest.
When Brand Isn’t Enough: Hardware, Patents, and Category Control
The tension between brand and IP is another recurring theme in longevity and wellness. Many companies pour vast resources into community building, influencer partnerships, and software experiences, hoping that a passionate user base will insulate them from competition. Real‑world disputes suggest the picture is more complex.
Consider hardware‑led ecosystems in the wearable and sensor space. In high‑profile conflicts, companies with robust hardware architectures and patents have sometimes prevailed over competitors that leaned heavily on brand, community, and software differentiation alone.
Even when the challenger created impressive engagement and a polished app layer, weak foundational IP left them constrained in key markets or pushed into narrow feature sets.
The lesson for beauty and longevity founders is not to abandon brand or storytelling; these are still crucial for adoption and trust. It is to recognize that in deeply technical categories, brand cannot fully substitute for defensible underlying technology.
When someone else owns the foundational IP—on sensing methods, processing pipelines, or integrated systems—they may effectively control the board on which everyone else is playing.
The Visibility Paradox: How Founders Undermine Their Own IP
Perhaps the most counterintuitive risk in today’s landscape is not under‑sharing, but over‑sharing. In an era that celebrates building in public, founders are encouraged to speak at conferences, share pipeline slides on LinkedIn, publish preprints, and hop on every podcast. The unintended consequence is that many reveal more than they realize before their IP house is in order.
Public disclosure—through talks, white papers, pitch competitions, or even detailed investor decks that leak—can jeopardize patentability, particularly outside the United States. The U.S. offers limited grace periods; Europe, China, and many other jurisdictions are stricter, and the new WIPO treaty on genetic resources and associated traditional knowledge is adding additional layers of disclosure expectations around origin and indigenous contributions.
In a global industry obsessed with botanicals, marine actives, fermented ingredients, and traditional medicine, those shifts matter.
This creates a genuine paradox: visibility is necessary to raise capital, attract talent, and build trust, yet it can quietly erode the very defensibility that makes the business investable. The question “How much should founders reveal?” is no longer a tactical PR consideration; it is a strategic governance issue that boards and legal teams must actively manage.
Read more: From Products to Protocols: The Next Evolution of Consumer Health
What Investors Are Reading Between the Lines
When longevity investors open a data room in 2026, they are not just scanning for a patent number on the front page. They are reading between the lines for three deeper signals.
First, freedom to operate. The core question is not “Do you have IP?” but “Can you sell this at scale without being blocked or sued in key markets?” A solid FTO analysis shows that the team has mapped the existing patent landscape and understands where it can move freely, where it must license, and where it should not step at all.
Second, clear ownership. In a sector where much innovation comes out of universities, hospitals, and complex collaborations, the question “Who owns this?” is far from trivial. Ambiguous arrangements with academic institutions, contract researchers, or former co‑founders can derail deals when they surface at the eleventh hour.
Third, layered protection. Rather than relying on a single flagship patent, sophisticated investors look for a portfolio mindset: patents, trademarks, copyrights, trade secrets, and sometimes data or process moats that reinforce one another.
This multi‑layered approach is especially important in beauty and wellness, where some elements are harder to patent but can still be defended through brand, narrative, and proprietary protocols.
The Next Frontier: Sourcing, Ethics, and the WIPO Treaty
Beyond traditional IP mechanics, a major emerging theme is the intersection of intellectual property with ethics and biodiversity. The new WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge, adopted in 2024, introduces mandatory disclosure requirements for patents based on genetic resources and associated traditional knowledge.
For beauty and longevity brands sourcing botanicals, marine actives, adaptogens, fermented ingredients, or traditional medicines, this is not an abstract legal curiosity.
It signals a future in which companies may be expected—or required—to disclose the country of origin and the indigenous or local knowledge on which their inventions rely, and to show how benefits are shared. Investors are already starting to ask sharper questions about sourcing, indigenous partnerships, and compliance with emerging frameworks.
This dovetails with broader movements in regenerative beauty, ethical sourcing, and sustainability. The brands that win in the next decade are likely to be those that can align cutting‑edge science with robust IP, transparent sourcing, and credible benefit‑sharing narratives, instead of treating these as separate conversations.
From Discovery to Ownership
Taken together, these trends point to a single, overarching shift: the longevity industry often celebrates discovery, but investors increasingly fund ownership. Data, biomarkers, and breakthrough mechanisms are necessary but not sufficient. The companies that create durable value will be the ones that ask, early and often, “If this works, what stops someone bigger from copying it?”
As longevity moves from niche science into mainstream beauty, wellness, diagnostics, and consumer health, IP strategy will sit alongside clinical evidence and user experience as a core discipline. That does not diminish the romance of discovery; it ensures that when we do find something truly transformative, we have the structures in place to bring it safely, ethically, and sustainably to the millions of people whose lives it might change.
What part of this IP conversation feels most urgent for your own work right now: protecting ingredients and systems, managing visibility, or navigating new rules around sourcing and traditional knowledge?
Two days left: nominate before the July 15 final deadline. Finalists announced at Zurich, Sept 10.
